(HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online in Practical Radiation Oncology, evidence-based recommendations are ...

Patients with low-grade upper tract urothelial carcinoma receiving primary treatment with 6 once-weekly pyelocalyceal doses ...

A phase 1 clinical trial led by City of Hope®, one of the largest and most advanced cancer research and treatment ...

While randomized comparative trials are needed, a relatively new treatment option for upper urinary tract cancers shows ...

Mitomycin C gel instillation is a nonsurgical, kidney-sparing primary treatment option for patients with low-grade upper tract urothelial carcinoma (UTUC).

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of ...

PURPOSE: To review the literature on the adjuvant use of mitomycin C (MMC) during dacryocystorhinostomy (DCR) in adults with primary nasolacrimal duct obstructions (NLDOs) to determine the ...

Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer ...

Electromotive intravesical delivery of mitomycin C (eMMC) has been proposed as a method to improve drug delivery across biological membranes and to increase drug accumulation in bladder tissue.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers ...

Kohen's team explored pirfenidone (PFD) for its antifibrotic activity, aiming to reduce scarring around GDDs without the ...